Second-line ramucirumab therapy for advanced hepatocellular carcinoma (REACH): an East Asian and non-East Asian subgroup analysis
Oncotarget, 2016-11, Vol.7 (46), p.75482-75491Copyright: © 2016 Park et al. 2016 ;ISSN: 1949-2553 ;EISSN: 1949-2553 ;DOI: 10.18632/oncotarget.12780 ;PMID: 27776351
Full text available